Effectiveness,Compliance,and Safety of Dextrose Prolotherapy for Knee Osteoarthritis: A Meta-Analysis and Metaregression of Randomized Controlled Trials
Restricted accessResearch articleFirst published online June, 2022
Effectiveness,Compliance,and Safety of Dextrose Prolotherapy for Knee Osteoarthritis: A Meta-Analysis and Metaregression of Randomized Controlled Trials
This study assessed the effectiveness, compliance, and safety of dextrose prolotherapy for patients with knee osteoarthritis.
Data sources
PubMed, EMBASE, the Cochrane Library Database, and the Scopus database from their inception to December 31, 2021.
Methods
This study was conducted in accordance with the guidelines recommended by the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. Randomized controlled trials regarding the effectiveness of dextrose prolotherapy in knee osteoarthritis were identified. The included trials were subjected to meta-analysis. Risk of bias was assessed using the Cochrane risk of bias tool. Subgroup and random-effects metaregression analyses were performed to explore any heterogeneity (I2) of treatment effects across studies.
Results
A total of 14 trials enrolling 978 patients were included in the meta-analysis. Compared with placebo injection and noninvasive control therapy, dextrose prolotherapy had favorable effects on pain, global function, and quality of life during the overall follow-up. Dextrose prolotherapy yielded greater reductions in pain score over each follow-up duration than did the placebo. Compared with other invasive therapies, dextrose prolotherapy generally achieved comparable effects on pain and functional outcomes for each follow-up duration.
Subgroup results indicated that combined intra-articular and extra-articular injection techniques may have stronger effects on pain than a single intra-articular technique.
Conclusions
Dextrose prolotherapy may have dose-dependent and time-dependent effects on pain reduction and function recovery, respectively, in patients with knee osteoarthritis. Due to remarkable heterogeneity and the risk of biases across the included trials, the study results should be cautiously interpreted.
BannuruRROsaniMCVaysbrotEE, et al.OARSI Guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage2019; 27: 1578–1589. 2019/07/07.
2.
LaneNEBrandtKHawkerG, et al.OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage2011; 19: 478–482. 2011/03/15. .
3.
Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of rheumatology subcommittee on osteoarthritis guidelines. Arthritis Rheum2000; 43: 1905–1915. 2000/10/03.
4.
HeWWKuangMJZhaoJ, et al.Efficacy and safety of intraarticular hyaluronic acid and corticosteroid for knee osteoarthritis: a meta-analysis. Int J Surg2017; 39: 95–103. 2017/02/01.
5.
WerneckeCBraunHJDragooJL. The effect of intra-articular corticosteroids on articular cartilage: a systematic review. Orthop J Sports Med2015; 3: 2015. /12/18.
6.
TopolGAReevesKDHassaneinKM. Efficacy of dextrose prolotherapy in elite male kicking-sport athletes with chronic groin pain. Arch Phys Med Rehabil2005; 86: 697–702. 2005/04/14.
7.
ReevesKDHassaneinK. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. Altern Ther Health Med2000; 6: 68–74. 77–80. 2000/03/11.
8.
ReevesKDHassaneinK. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger (DIP. PIP, and trapeziometacarpal) joints: evidence of clinical efficacy. J Altern Complement Med2000; 6: 311–320. 2000/09/08.
9.
BanksA. A rationale for prolotherapy. J Orthop Med1991; 13: 54–59.
10.
JensenKTRabagoDPBestTM, et al.Early inflammatory response of knee ligaments to prolotherapy in a rat model. J Orthop Res2008; 26: 816–823. 2008/02/02.
11.
JensenKTRabagoDPBestTM, et al.Response of knee ligaments to prolotherapy in a rat injury model. Am J Sports Med2008; 36: 1347–1357. 2008/03/04.
12.
ParkYSLimSWLeeIH, et al.Intra-articular injection of a nutritive mixture solution protects articular cartilage from osteoarthritic progression induced by anterior cruciate ligament transection in mature rabbits: a randomized controlled trial. Arthritis Res Ther2007; 9: 2007. /01/30.
13.
TsaiSWHsuYJLeeMC, et al.Effects of dextrose prolotherapy on contusion-induced muscle injuries in mice. Int J Med Sci2018; 15: 1251–1259. 2018/08/21.
14.
Waluyo YBBukhariA, et al.Changes in levels of cartilage oligomeric proteinase and urinary C-terminal telopeptide of type II collagen in subjects with knee osteoarthritis after dextrose prolotherapy: a randomized controlled trial. J Rehabil Med2021; 53:jrm00196. 2021/04/28.
15.
TopolGAPodestaLAReevesKD, et al.Chondrogenic effect of intra-articular hypertonic-dextrose (prolotherapy) in severe knee osteoarthritis. Pm r2016; 8: 1072–1082. 2016/04/09.
16.
HanDSLeeCHShiehYD, et al. A role for substance P and acid-sensing ion channel 1a in prolotherapy with dextrose-mediated analgesia in a mouse model of chronic muscle pain. Pain2021. doi:10.1097/j.pain.0000000000002440
17.
RabagoDSlattengrenAZgierskaA. Prolotherapy in primary care practice. Prim Care2010; 37: 65–80. 2010/03/02.
18.
Arias-VázquezPITovilla-ZárateCALegorreta-RamírezBG, et al.Prolotherapy for knee osteoarthritis using hypertonic dextrose vs other interventional treatments: systematic review of clinical trials. Advances In Rheumatology (London. England2019; 59: 2019. /08/21.
19.
WeeTCNeoEJRTanYL. Dextrose prolotherapy in knee osteoarthritis: a systematic review and meta-analysis. J Clin Orthop Trauma2021; 19: 108–117. 2021/05/29.
20.
ShamseerLMoherDClarkeM, et al.Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. Br Med J2015; 350: 2015. /01/04.
21.
BellamyNBuchananWWGoldsmithCH, et al.Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol1988; 15: 1833–1840. 1988/12/01.
22.
WeiglMEwertTKleinschmidtJ, et al.Measuring the outcome of health resort programs. J Rheumatol2006; 33: 764–770. 2006/04/04.
23.
HigginsJPTThomasJChandlerJet al. (eds.). Cochrane Handbook for Systematic Reviews of Interventions. version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
24.
HigginsJPTAltmanDGGøtzschePC, et al.The cochrane collaboration’s tool for assessing risk of bias in randomised trials. Br Med J2011; 343: d5928. doi:10.1136/bmj.d5928.
25.
DeeksJJHigginsJPTAltmanDG. Analysing data and undertaking meta-analyses. In: HigginsJPTThomasJChandlerJ, et al. (eds) Cochrane Handbook For Systematic Reviews Of Interventions. version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook.
26.
EggerMDavey SmithGSchneiderM, et al.Bias in meta-analysis detected by a simple, graphical testBr Med J1997; 315: 629–634. 1997/10/06.
27.
HartungJKnappG. On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med2001; 20: 1771–1782.
28.
ViechtbauerW. Conducting meta-analyses in R with the metafor package. J Stat Softw2010; 36: 1–48.
29.
DumaisRBenoitCDumaisA, et al.Effect of regenerative injection therapy on function and pain in patients with knee osteoarthritis: a randomized crossover study. Pain medicine (Malden. Mass2012; 13: 990–999. 2012/07/05.
30.
EroğluAAylinSDurmuşB. Platelet-rich plasma vs prolotherapy in the management of knee osteoarthritis: randomized placebo-controlled trial. Spor Hekimliği Dergisi2016; 51: 034–043.
31.
HashemiMJaliliPMennatiS, et al.The effects of prolotherapy With hypertonic dextrose versus prolozone (intraarticular ozone) in patients With knee osteoarthritis. Anesth Pain Med2015; 5: 2015. /11/21.
32.
HashemiSMMadadiFRazaviS, et al.Intra-articular hyaluronic acid injections Vs. Dextrose prolotherapy in the treatment of osteoarthritic knee pain. Tehran University Medical Journal2012; 70: 119–125.
33.
PishgahiAAbolhasanRShakouriSK, et al.Effect of dextrose prolotherapy, platelet rich plasma and autologous conditioned Serum on knee osteoarthritis: a randomized clinical trial. Iran J Allergy Asthma Immunol2020; 19: 243–252. 2020/07/04.
34.
RabagoDKijowskiRWoodsM, et al.Association between disease-specific quality of life and magnetic resonance imaging outcomes in a clinical trial of prolotherapy for knee osteoarthritis. Arch Phys Med Rehabil2013; 94: 2075–2082. 2013/07/16.
35.
RabagoDPattersonJJMundtM, et al.Dextrose prolotherapy for knee osteoarthritis: a randomized controlled trial. Ann Fam Med2013; 11: 229–237. 2013/05/22.
36.
RahimzadehPImaniFFaizSH, et al.Investigation the efficacy of intra-articular prolotherapy with erythropoietin and dextrose and intra-articular pulsed radiofrequency on pain level reduction and range of motion improvement in primary osteoarthritis of knee. J Res Med Sci : The Offic J Isfahan Univ Med Sci2014; 19: 696–702. 2014/11/26.
37.
RahimzadehPImaniFFaizSHR, et al.The effects of injecting intra-articular platelet-rich plasma or prolotherapy on pain score and function in knee osteoarthritis. Clin Interv Aging2018; 13: 73–79. 2018/01/31.
38.
RezasoltaniZAziziSNajafiS, et al.Physical therapy, intra-articular dextrose prolotherapy, botulinum neurotoxin, and hyaluronic acid for knee osteoarthritis: randomized clinical trial. Int J Rehabil Res2020; 43: 219–227. 2020/08/11.
39.
SertATSenEIEsmaeilzadehS, et al.The effects of dextrose prolotherapy in symptomatic knee osteoarthritis: a randomized controlled study. J Alternative And Complem Med (New York. NY2020; 26: 409–417. 2020/04/01.
40.
SitRWSWuRWKRabagoD, et al.Efficacy of intra-articular hypertonic dextrose (prolotherapy) for knee osteoarthritis: a randomized controlled trial. Ann Fam Med2020; 18: 235–242. 2020/05/13.
41.
HosseiniBTaheriMPourroustaei ArdekaniR, et al.Periarticular hypertonic dextrose vs intraarticular hyaluronic acid injections: a comparison of two minimally invasive techniques in the treatment of symptomatic knee osteoarthritis. Open Access Rheumatology : Research And Reviews2019; 11: 269–274. 2019/12/11.
42.
SitRWChungVReevesKD, et al.Hypertonic dextrose injections (prolotherapy) in the treatment of symptomatic knee osteoarthritis: a systematic review and meta-analysis. Sci Rep2016; 6: 2016. /05/06.
43.
FarpourHRFereydooniF. Comparative effectiveness of intra-articular prolotherapy versus peri-articular prolotherapy on pain reduction and improving function in patients with knee osteoarthritis: a randomized clinical trial. Electron Physician2017; 9: 5663–5669. 2018/02/07.
44.
RezasoltaniZTaheriMMofradMK, et al.Periarticular dextrose prolotherapy instead of intra-articular injection for pain and functional improvement in knee osteoarthritis. J Pain Res2017; 10: 1179–1187. 2017/05/30.
45.
RabagoDMundtMZgierskaA, et al.Hypertonic dextrose injection (prolotherapy) for knee osteoarthritis: long term outcomes. Complement Ther Med2015; 23: 388–395. 2015/06/09.
46.
LiuYKTiptonCMMatthesRD, et al.An in situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junction strength. Connect Tissue Res1983; 11: 95–102. 1983/01/01.
47.
LyftogtJ. Subcutaneous prolotherapy treatment of refractory knee, shoulder, and lateral elbow pain. Australas Musculoskeletal Med.2007; 12: 110–112.
48.
FuRGartlehnerGGrantM, et al.Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective health care program. J Clin Epidemiol2011; 64: 1187–1197. 2011/04/12.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
